Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1952
Title: Is prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: An analysis informed by the proPSMA Trial
Authors: Freydenberg, Mark
Lawrentschuk, Nathan
Murphy, Declan
Other Authors: de Feria Cardet, Rafael
Hofman, Michael
Segard, Tatiana
Yim, Jackie
Williams, Scott
Francis, Roslyn
De Abreu Lourenco, Richard
Keywords: Prostate-Specific Membrane Antigen
PSMA
Positron Emission Tomography
Computed Tomography
Cost-Effectiveness
Imaging
Economic Evaluation
High Risk
Prostate Cancer
Metastases
proPSMA Study
Scan
Staging
Accuracy
EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Dec-2020
Publisher: Elsevier
Citation: Eur Urol . 2020 Dec 16;S0302-2838(20)30946-5
Abstract: Background: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use. Objective: To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging. Design, setting, and participants: A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or 68Ga-PSMA-11 PET/CT with planned health economics data collected. The cost-effectiveness analysis was conducted from an Australian societal perspective. Intervention: 68Ga-PSMA-11 PET/CT compared with conventional imaging (CT and bone scan). Outcome measurements and statistical analysis: The primary outcome from proPSMA was diagnostic accuracy (nodal and distant metastases). This informed a decision tree analysis of the cost per accurate diagnosis. Results and limitations: The estimated cost per scan for PSMA PET/CT was AUD$1203, which was less than the conventional imaging cost at AUD$1412. PSMA PET/CT was thus dominant, having both better accuracy and a lower cost. This resulted in a cost of AUD$959 saved per additional accurate detection of nodal disease, and AUD$1412 saved for additional accurate detection of distant metastases. The results were most sensitive to variations in the number of men scanned for each 68Ga-PSMA-11 production run. Subsequent research is required to assess the long-term costs and benefits of PSMA PET/CT-directed care. Conclusions: PSMA PET/CT has lower direct comparative costs and greater accuracy compared to conventional imaging for initial staging of men with high-risk prostate cancer. This provides a compelling case for adopting PSMA PET/CT into clinical practice. Patient summary: The proPSMA study demonstrated that prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) better detects disease that has spread beyond the prostate compared with conventional imaging. Our analysis shows that PSMA PET/CT is also less costly than conventional imaging for the detection of disease spread. This research was presented at the European Association of Nuclear Medicine Scientific Meeting in October 2020
URI: http://hdl.handle.net/11434/1952
DOI: 10.1016/j.eururo.2020.11.043
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/33341285/
ISSN: 0302-283
Journal Title: European Urology
Type: Journal Article
Affiliated Organisations: Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australia
Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
Sir Charles Gardiner Hospital, Perth, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Camperdown, Australia
Department of Medicine, University of Queensland, Brisbane, Australia
School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
Cabrini Institute, Cabrini Health, Malvern, Australia
Department of Surgery, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
Type of Clinical Study or Trial: Review
Appears in Collections:UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.